Focal HIFU for Treatment of Localised Prostate Cancer: A Multi-centre Registry Experience
BAUS ePoster online library. Guillaumier S. 06/30/16; 132006; P10-6
Ms. Stephanie Guillaumier
Ms. Stephanie Guillaumier
Login now to access Regular content available to all registered users.

You may also access this content "anytime, anywhere" with the Free MULTILEARNING App for iOS and Android
Abstract
Discussion Forum (0)
Rate & Comment (0)
P10-6

INTRODUCTION: Focal therapy using HIFU has been shown to provide encouraging short-term disease control with a low genito-urinary side effect profile. We report on the medium-term oncological and functional outcomes from our UK prospective academic HIFU registry across 8 centres. .

METHODS: 625 patients diagnosed with T1aN0MO to T3bN0M0 prostate cancer after multi-parametric MRI, transperineal and/or MR-targeted biopsies and were treated with focal HIFU. 

RESULTS: Of 625 patients, 80 (13%), 491 (81%) and 39 (6%) had low, intermediate and high-risk disease. At 1-2 years and 2-3 years post-op, at baseline and follow-up; 305 (97%) and 241 (98%) were pad-free, respectively. At 1-2 years and 2-3 years after focal-HIFU, continence status was 209 (83%), and 156 (80%) were pad-free, leak-free continent. 

At 1-2 years and 2-3 years, at baseline and follow-up; 138 (84%) and 87 (86%) maintained erectile function, respectively. Two (0.8%) developed a recto-urethral fistula of which one healed with urinary diversion alone and the second required operative reconstruction.

Overall, 29/625 (4.6%) were found to have in-field recurrence on 12 month post-op biopsies. 16 (2.6) out-of-field de novo disease or progression and 11 (1.8%) had both. 122 (20%) had a further focal-HIFU treatment, whilst 44 (7%) transitioned to radical whole-gland therapy. The metastasis-free survival, prostate-cancer specific survival and overall survival at 5 years were 97%, 100% and 99% respectively.

CONCLUSIONS: Focal HIFU has acceptable rates of cancer control in men with clinically significant prostate cancer with a low genito-urinary side-effect profile in the medium-term and across a number of centres. 

P10-6

INTRODUCTION: Focal therapy using HIFU has been shown to provide encouraging short-term disease control with a low genito-urinary side effect profile. We report on the medium-term oncological and functional outcomes from our UK prospective academic HIFU registry across 8 centres. .

METHODS: 625 patients diagnosed with T1aN0MO to T3bN0M0 prostate cancer after multi-parametric MRI, transperineal and/or MR-targeted biopsies and were treated with focal HIFU. 

RESULTS: Of 625 patients, 80 (13%), 491 (81%) and 39 (6%) had low, intermediate and high-risk disease. At 1-2 years and 2-3 years post-op, at baseline and follow-up; 305 (97%) and 241 (98%) were pad-free, respectively. At 1-2 years and 2-3 years after focal-HIFU, continence status was 209 (83%), and 156 (80%) were pad-free, leak-free continent. 

At 1-2 years and 2-3 years, at baseline and follow-up; 138 (84%) and 87 (86%) maintained erectile function, respectively. Two (0.8%) developed a recto-urethral fistula of which one healed with urinary diversion alone and the second required operative reconstruction.

Overall, 29/625 (4.6%) were found to have in-field recurrence on 12 month post-op biopsies. 16 (2.6) out-of-field de novo disease or progression and 11 (1.8%) had both. 122 (20%) had a further focal-HIFU treatment, whilst 44 (7%) transitioned to radical whole-gland therapy. The metastasis-free survival, prostate-cancer specific survival and overall survival at 5 years were 97%, 100% and 99% respectively.

CONCLUSIONS: Focal HIFU has acceptable rates of cancer control in men with clinically significant prostate cancer with a low genito-urinary side-effect profile in the medium-term and across a number of centres. 

Code of conduct/disclaimer available in General Terms & Conditions

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies